Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848669 | 0.91 | MEN1 (0.51) | ALDH1A1RXFP1MEN1KMT2AMAPT | |
| SCHEMBL13411546 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL9917266 | 0.86 | RXFP1 (0.44) | ALDH1A1RXFP1MEN1KMT2AMAPT | |
| SCHEMBL12109340 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL20420548 | 0.85 | RXFP1 (0.42) | ALDH1A1RXFP1MEN1KMT2AMAPT | |
| SCHEMBL23011511 | 0.84 | LMNA (0.49) | ALDH1A1RXFP1MEN1KMT2AMAPT | |
| SCHEMBL12452413 | 0.83 | RXFP1 (0.41) | ALDH1A1RXFP1MEN1KMT2AMAPT | |
| SCHEMBL21788135 | 0.83 | TOP2A (0.51) | ALDH1A1MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL18090988 | 0.83 | RXFP1 (0.47) | ALDH1A1RXFP1MEN1KMT2AMAPT | |
| SCHEMBL2968894 | 0.82 | MEN1 (0.63) | ALDH1A1MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SEAGEN INC (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2023077126-A1 | TRANS-CYCLOOCTENE CONJUGATES | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077129-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023040793-A1 | ANTI-INFLAMMATORY COMPOUND AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023001223-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022262789-A1 | ANTITUMOR COMPOUND AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-20120329094-A1 | Anti-CD22 Antibodies And Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2012-11-08 | — | — | US | disclosed |
| US-8226945-B2 | Antibodies and immunoconjugates and uses therefor | GENENTECH, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110206658-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN | CROWLEY CRAIG | 2011-08-25 | — | — | US | disclosed |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110171125-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110142859-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20090280056-A1 | Antibodies and immunoconjugates and uses therefor | GENENTECH, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090117100-A1 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates | GENENTECH, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280056-A1 | Antibodies and immunoconjugates and uses therefor | STXBP1, WASF2, SDAD1 | ALDH1A1 3246/4885RXFP1 963/4885MEN1 766/4885 |
| US-20090117100-A1 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates | PCTP, LNPEP, SLC3A2 | ALDH1A1 1354/4885RXFP1 3450/4885MEN1 3334/4885 |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | ALDH1A1 1069/4885RXFP1 4627/4885MEN1 636/4885 |
| US-20110142859-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | ALDH1A1 404/4885RXFP1 2243/4885MEN1 2249/4885 |
| US-20110171125-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | ALDH1A1 3561/4885RXFP1 1162/4885MEN1 1668/4885 |
| US-20230173093-A1 | CHARGE VARIANT LINKERS | SSB, UACA, CDA | ALDH1A1 1439/4885RXFP1 4594/4885MEN1 515/4885 |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | EPOR, TTPA, PDS5A | ALDH1A1 859/4885RXFP1 3719/4885MEN1 1214/4885 |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885RXFP1 3481/4885MEN1 693/4885 |
| US-20110206658-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN | HCLS1, CD47, MCL1 | ALDH1A1 2567/4885RXFP1 4750/4885MEN1 355/4885 |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885RXFP1 3481/4885MEN1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.